Quinapril improves endothelial function in postmenopausal hypertensive patients

Kidney and Blood Pressure Research

Volumn 31, Issue 4, 2008, Pages 226-233

  Farkas, Katalin ^a   Fábián, Emília ^b   Nagy, Lajos ^c  

^a Szent Imre Hospital   (Hungary)

^b Department of Cardiology   (Hungary)

^c Markusovszky Teaching Hospital   (Hungary)

Author keywords

Endothelial function; Flow mediated dilation; Hypertension; Postmenopausal women; Quinapril

Indexed keywords

ACETYLCHOLINE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NITROPRUSSIDE SODIUM; PLASMINOGEN ACTIVATOR INHIBITOR 1; QUINAPRIL; TRIACYLGLYCEROL;

ADULT; AGED; ARTERY DILATATION; ARTERY ENDOTHELIUM; ARTERY RESISTANCE; ARTICLE; BRACHIAL ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFUSION; COUGHING; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; OUTPATIENT CARE; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SKIN BLOOD FLOW; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; URTICARIA;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BRACHIAL ARTERY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION; MIDDLE AGED; POSTMENOPAUSE; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME; VASODILATION;

EID: 45749157684     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000141927     Document Type: Article

References (36)

1. Adams MR, Celermajer DS: Detection of presymptomatic atheroscleosis: a current perspective. Clin Sci (Colch) 1999;97:615-624.
2. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE: Endothelium-dependent dilatation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 1994;24:1468-1474.
3. Colditz GA, Wilett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH: Menopause and the risk of coronary heart disease in women. N Engl J Med 1987;316:1105-1110.
4. Sorensen KE, Dorup I, Hermann AP, Mosekilde I: Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function. Circulation 1998;97:1234-1238.
5. Bush DE, Jones CE, Bass KM, Walters GK, Bruza JM, Ouyang P: Estrogen replacement reverses endothelial dysfunction in postmenopausal women. Am J Med 1998;104:552-558.
6. Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, Yeung AC, Creager MA: Estrogen improves endothelium-dependent, flow mediated vasodilatation in postmenopausal women. Ann Intern Med 1994;121:936-941.
7. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghof E: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.
8. Rossouw JE, Anderson AG, Prentice RI, La-Croix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
9. Mancini GB, Henry GC, Macaya C, et al: Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996;94:258-265.
10. Nagy L, Bajkó S, Fábián E, Farkas K, Fazekas Á, Forster T, Járai Z, Kolossváry E, Kovács I, Pálinkás A, Pécsvárady Z, Rónaszéki A, Varga A, Vereczkey G: Magyar konszenzus az artéria brachialis áramlásfüggocombining double acute accent 'flow mediated' vasodilatációjának vizsgálatához. Érbetegségek 2003;10:47-50.
11. Celermajer DS, et al: Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-1115.
12. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R; International Brachial Artery Reactivity Task Force: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-265.
13. Farkas K, Kolossváry E, Járai Z, Nemcsik J, Farsang CS: Non-invasive assessment of microvascular function by laser Doppler flowmetry in patients with essential hypertension. Atherosclerosis 2004;173:97-102.
14. Kubli S, Beranrd W, Dalle-Ave A, Feihl F: Reproducibility of laser Doppler imaging of skin blood flow as a tool to assess endothelial function. J Cardiovasc Pharmacol 2000;36:640-648.
15. Hornig B, Landmesser U, Kohler C, et al: Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 2001;103:799-805.
16. Erzen B, Gradisek P, Poredos P, Sabovic M: Treatment of essential arterial hypertension with enalapril does not result in normalization of endothelial dysfunction of the conduit arteries. Angiology 2006;57:187-192.
17. Ghiadoni L, Huang Y, Magagna A, Buralli S, Taddei S, Salvetti A: Effect of acute blood pressure reduction on endothelial function in the brachial artery of patients with essential hypertension. J Hypertens 2001;19:547-551.
18. Nickenig G, Stäblein A, Wassmann S, Wyen C, Müller C, Böhm M: Acute effects of ACE inhibition on coronary endothelial dysfunction. J Renin Angiotensin Aldosterone Syst 2000;1:361-364.
19. Aznaouridis KA, Stamatelopoulos KS, Karatzis EN, Protogerou AD, Papamichael CM, Lekakis JP: Acute effects of renin-angiotensin system blockade on arterial function in hypertensive patients. J Hum Hypertens 2007;21:654-663.
20. Hermann TS, Li W, Dominguez H, Ihlemann N, Rask-Madsen C, Major-Pedersen A, Nielsen DB, Hansen KW, Hawkins M, Kober L, Torp-Pedersen C: Quinapril treatment increases insulin-stimulated endothelial function and adiponectin gene expression in patients with type 2 diabetes. J Clin Endocrinol Metab 2006;91:1001-1008.
21. Dzau VJ, Bernstein K, Celermajer D, Cohen J, Dahlöf B, Deanfield J, Diez J, Drexler H, Ferrari R, van Gilst W, Hansson L, Hornig B, Husain A, Johnston C, Lazar H, Lonn E, Lüscher T, Mancini J, Mimran A, Pepine C, Rabelink T, Remme W, Ruilope L, Ruzicka M, Schunkert H, Swedberg K, Unger T, Vaughan D, Weber M; Working Group on Tissue Angiotensin-Converting Enzyme, International Society of Cardiovascular Pharmacotherapy: The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 2001;88:1L-820L.
22. Anderson TJ, Elstein E, Haber H, Charbonneau F: Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 2000;35:60-66.
23. Kannel WB, Wilson PW: Risk factors that attenuate the female coronary disease advantage. Arch Intern Med 1995;155:57-61.
24. Hinojosa-Laborde C, Craig T, Zheng W, Ji H, Haywood JR, Sandberg K: Ovariectomy augments hypertension in aging female Dahl salt-sensitive rats. Hypertension 2004;44:405-409.
25. Kalantaridou SN, Naka KK, Papanikolaou E, Kazakos N, Kravariti M, Calis KA, Paraskevaidis EA, Sideris DA, Tsatsoulis A, Chrousos GP, Michalis LK: Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy. J Clin Endocrinol Metab 2004;89:3907-3913.
26. Mendelsohn ME, Karas RH: Mechanisms of disease: the potential effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-1811.
27. Khalil RA: Sex hormones as potential modulators of vascular function in hypertension. Hypertension 2005;46:249-254.
28. Hermenegildo C, Oviedo PJ, Cano A: Cyclooxygenases regulation by estradiol on endothelium. Curr Pharm Des 2006;12:205-215.
29. Nilsson S, Gustafsson JA: Estrogen receptor transcription and transactivation. Basic aspects of estrogen action. Breast Cancer Res 2000;2:360-366.
30. Barchiese F, Jackson EK, Gillespie DJ, Zacharia LC, Fingerle J, Dubbey RK: Methoxyestradiols mediate estradiol-induced antimitogenesis in human aortic SMCs. Hypertension 2002;39:874-879.
31. Sherwood A, Bower JK, McFetridge-Durdle J, Blumenthal JA, Newby LK, Hinderliter AL: Age moderates the short-term effects of transdermal 17beta-estradiol on endothelium-dependent vascular function in postmenopausal women. Arterioscler Thromb Vasc Biol 2007;27:1782-1787.
32. Yeboah J, Reboussin DM, Waters D, Kowalchuk G, Herrington DM: Effects of estrogen replacement with and without medroxyprogesterone acetate on brachial flow-mediated vasodilator responses in postmenopausal women with coronary artery disease. Am Heart J 2007;153:439-444.
33. Brown NJ, Abbas A, Byrne D, Schoenhard JA, Vaughan DE: Comparative effects of estrogen and angiotensin-converting enzyme inhibition on plasminogen activator inhibitor-1 in healthy postmenopausal women. Circulation 2002;105:304-309.
34. Tsikouris JP, Suarez JA, Meyerrose GE, Ziska M, Fike D, Smith J: Questioning a class effect: does ACE inhibitor tissue penetration influence the degree of fibrinolytic balance alteration following an acute myocardial infarction? J Clin Pharmacol 2004;44:150-157.
35. Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE: Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 1998;32:965-971.
36. Sakata K, Pawlak R, Urano T, Takada A: Effects of a long-term pharmacological interruption of the renin-angiotensin system on the fibrinolytic system in essential hypertension. Pathophysiol Haemost Thromb 2002;32:67-75.